Advanced Search

Study Preview



Study Title and Description

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania



Key Questions Addressed
1 Evidence map
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
Author Delbello M
Country
Year 2017
Numbers Pubmed ID: NCT00393978

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Evidence Map
Arms
Number Title Description Comments
1 Quetiapine_Placebo
  • Comments Comments (
    0
    ) |
2 Quetiapine_Topiramate
  • Comments Comments (
    0
    ) |

Design Details
Question... Follow Up Answer Follow-up Answer
Should this citation be included? Yes
  • Comments Comments (
    0
    ) |
Does this paper originate from a primary study of interest? ... Trial registry number ... NCT00393978
  • Comments Comments (
    0
    ) |
Ages eligible (in years) 12
  • Comments Comments (
    0
    ) |
21
  • Comments Comments (
    0
    ) |
Total sample size (in all arms) 75
  • Comments Comments (
    0
    ) |
Age distribution of enrolled population (in years) 17.4
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Substance used Cannabis
  • Comments Comments (
    0
    ) |
Cannabis
  • Comments Comments (
    0
    ) |
Cannabis
  • Comments Comments (
    0
    ) |
Interventions studied? Pharmacologic
  • Comments Comments (
    0
    ) |
Pharmacologic
  • Comments Comments (
    0
    ) |
Pharmacologic
  • Comments Comments (
    0
    ) |
Outcome? Self report of use/abstinence and/or intensity
  • Comments Comments (
    0
    ) |
Adverse effects
  • Comments Comments (
    0
    ) |
Self report of use/abstinence and/or intensity
  • Comments Comments (
    0
    ) |
Adverse effects
  • Comments Comments (
    0
    ) |
Self report of use/abstinence and/or intensity
  • Comments Comments (
    0
    ) |
Adverse effects
  • Comments Comments (
    0
    ) |
Age variation of enrolled population (in years) 0.2
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Study type RCT
  • Comments Comments (
    0
    ) |
Is any arm a brief intervention (or single session)? No
  • Comments Comments (
    0
    ) |
Income level of country(ies) of origin Upper income
  • Comments Comments (
    0
    ) |
Upper income
  • Comments Comments (
    0
    ) |
Upper income
  • Comments Comments (
    0
    ) |




Results & Comparisons


Results Data
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 5 4
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 0 1
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 1 0
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 20 12
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 20 12
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 0 5
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 30 23
Outcome: Adverse event      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


4 months

N Analyzed 37 38
Counts 30 23
Outcome: cannabis use days      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


0 months

N Analyzed 37 38
Mean
SD
SE


4 months

N Analyzed 37 38
Mean
SD
SE
Outcome: cannabis use joints      Population: All Participants
Time Point Measure Quetiapine_Placebo Quetiapine_Topiramate


0 months

N Analyzed 37 38
Mean
SD
SE


4 months

N Analyzed 37 38
Mean
SD
SE


Quality Dimensions
Dimension Value Notes Comments
Intention-to-treat-analysis: Bias due to incomplete reporting and analysis according to group allocation Yes
  • Comments Comments (
    0
    ) |
Group similarity at baseline (selection bias): Selection bias due to dissimilarity at baseline for the most important prognostic indicators No Data
  • Comments Comments (
    0
    ) |
Co-interventions (performance bias): Performance bias because co-interventions were different across groups Yes
  • Comments Comments (
    0
    ) |
Compliance (performance bias): Performance bias due to inappropriate compliance with interventions across groups No Data
  • Comments Comments (
    0
    ) |
Timing of outcome assessments (detection bias): Detection bias because important outcomes were not measured at the same time across groups Yes
  • Comments Comments (
    0
    ) |
Additional Bias: Bias due to problems not covered elsewhere in the table. If yes, describe them in the Notes. No
  • Comments Comments (
    0
    ) |
Random sequence generation (selection bias): Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence Low Assume done correctly since factorial (more complex design)
  • Comments Comments (
    0
    ) |
Allocation concealment (selection bias): Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment Unclear
  • Comments Comments (
    0
    ) |
Blinding of participants (performance bias): Performance bias due to knowledge of the allocated interventions by participants during the study Low Triple blind
  • Comments Comments (
    0
    ) |
Blinding of personnel/ care providers (performance bias): Performance bias due to knowledge of the allocated interventions by personnel/care providers during the study. Low Triple blind
  • Comments Comments (
    0
    ) |
Blinding of outcome assessor (detection bias): Detection bias due to knowledge of the allocated interventions by outcome assessors. Low Triple blind
  • Comments Comments (
    0
    ) |
Incomplete outcome data (attrition bias): Attrition bias due to amount, nature or handling of incomplete outcome data High 52% Not Completed
  • Comments Comments (
    0
    ) |
Selective Reporting (reporting bias): Reporting bias due to selective outcome reporting need to check Use (Joints Per Week; Percent Days of Cannabis Use Per Week)
  • Comments Comments (
    0
    ) |

Quality Rating
Guideline Used Overall Rating